Home' Australian Pharmacist : Australian Pharmacist March 2016 Contents Australian Pharmacist March 2016 I ©Pharmaceutical Society of Australia Ltd.
In March Benzac is rolling out new
packaging on pharmacy shelves across
Australia and New Zealand. According to
Galderma, the revamped pack continues
to strongly communicate product
benefits and effectiveness, reinforcing
Benzac as a category leader in the
The Company says 85% of people
between the ages of 15 and 24 are
affected by acne. Ranging from mild
to severe, acne can be uncomfortable,
embarrassing and even debilitating.
It greatly impacts self-confidence,
especially among teenagers who are
dealing with a multitude of hormonal
changes as they reach puberty.
Benzac offers a solution for mild to
moderate acne sufferers with clinically
proven over-the-counter treatment gels,
cleansers, and moisturiser. Providing
effective and straight forward acne
solutions that go beyond superficial
relief, Benzac helps break the cycle of
acne with a three step approach to
deliver clearer skin.
KhenMeng Kon, Head of Medical at
Galderma said: ‘The dermatological
grade products in our AC gel range
contain the active ingredient benzoyl
peroxide to target the source of
pimples helping to clear problem skin.
We may have a fresh, new look on
shelves but pharmacy assistants can
let their customers know that Benzac
formulations remain the same. New
pack, same results.’
The Therapeutic Goods Administration
(TGA) has approved the first biologic
agent for the treatment of advanced
cervical cancer. Avastin (bevacizumab) is
indicated for the treatment of persistent,
recurrent or metastatic carcinoma of
the cervix in combination with standard
chemotherapy (paclitaxel and cisplatin
– or topotecan where cisplatin is not
tolerated or indicated).
Dr Catherine Shannon, Senior Medical
Oncologist at Mater Cancer Care Centre,
said that while cervical cancer was
mostly curable when caught early,
there were very few treatment options
available for women with advanced
Avastin in advanced cervical cancer
is supported by the GOG-240 study,
a phase III clinical trial that showed
women treated with chemotherapy
and Avastin achieved 17 months overall
survival compared to 13.3 months on
chemotherapy alone (HR, 0.71; 98% CI,
0.54 to 0.95).
A significant improvement
in progression free survival (8.2 vs. 5.9
months; HR, 0.67; 95% CI, 0.54 to 0.82)
and a higher response rate (48% vs.
36%) (relative probability of a response,
1.35; 95% CI, 1.08 to 1.68; p=0.008)
was also seen in patients who received
1. Tewari KS, et al. Improved Survival with Bevacizumab in
Advanced Cervical Cancer. NEJM 2014;370:734–43.
Sanofi Consumer Healthcare
Mersyndol has a comprehensive range
and is the only brand that breaks
the pain cycle by providing effective
pain relief through day and night.
The calmative action of doxylamine
in Mersyndol plays an important role
in enhancing the analgesic effects1
to offer migraine sufferers a restful
respite from pain. Mersyndol launched
a new campaign in October 2015,
that aims to educate pharmacists on
its unique position in using sleep to
break the pain cycle. The campaign
also helps pharmacists’ understand
the role of sleep in managing pain and
how Mersyndol breaks the pain cycle
through effective pain relief and its
additional calmative effect.
For more information about Mersyndol speak with
your Sanofi Consumer Healthcare Representative
or call 1800 732 273.
Before prescribing please review Full Product
Information available from Sanofi by calling 1800
Mersyndol (paracetamol; codeine phosphate;
doxylamine succinate) is indicated for
symptomatic relief from acute moderate to severe
pain, including tension headache and migraine, in
patients >12 years. Take 1-2 tablets every 4-6 hours
as needed; do not exceed 8 tablets in 24-hour
period. Contraindications: Hypersensitivity to the
active ingredients or any excipients, respiratory
depression, G6PD deficiency, breastfeeding,
CYP2D6 ultrarapid metabolisers.
Precautions: High doses; prolonged use; severe
hepatic or renal impairment; analgesic intolerance;
asthma; lactation; use in pregnancy (Category A).
Adverse effects: Anorexia, drowsiness, depression,
dizziness, sweating, and others. For more
information, see full PI.
1. Mersyndol Product Information
Links Archive Australian Pharmacist February 2016 Australian Pharmacist April 2016 Navigation Previous Page Next Page